ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 1 of 33
JMBS 2021, 6(4): 6–14
Medicine. Reviews

Current Data on the Directions of Therapy of Essential Hypertension in Patients with Metabolic Syndrome and COVID-19 and Possibilities for Prevention of Long-Term Complications

Ivanytska T. A. 1, Kazakov Yu. M. 1, Petrov Ye. Ye. 1, Burmak Yu. G. 2

The review article includes information on data on the treatment of patients with essential hypertension and manifestations of metabolic syndrome and their effectiveness in preventing the development of long-term complications of COVID-19. The pandemic of acute respiratory syndrome caused by SARS-CoV-2 requires changes in the approach to the treatment and prevention of metabolic syndrome and essential hypertension, as the presence of these comorbidities worsens the course and prognosis of infectious disease. Some pathogenetic links have been identified that affect these pathological conditions. Emphasis is placed on the key role of a balanced and healthy diet, as a component of a healthy lifestyle, in maintaining the optimal functional state of the cardiovascular system. It is also noted that the course of infectious disease caused by SARS-CoV-2 in patients with metabolic syndrome is more severe and more often leads to complications. Since COVID-19 is recognized as a multi-organ disease with a wide range of manifestations and long-term symptoms, data on the course of this disease in patients with hypertension and metabolic syndrome were analyzed. Endothelial dysfunction is highlighted as one of the pathogenetic links that combines essential hypertension, insulin resistance and atherosclerosis, and options for its correction are considered. Standards for the treatment of essential hypertension and metabolic syndrome in view of the COVID-19 pandemic are presented. Information on the ability of statins to increase glycemia with long-term use, especially in patients with metabolic syndrome, is given. Conclusion. A number of drugs that have antioxidant, vasodilator and anti-inflammatory properties that do not cause an increase in glycemia, including quercetin, have been proposed. Its positive effect on the level of blood pressure has been revealed, which implies its use as an adjunct to antihypertensive therapy. The combination of quercetin and vitamin C is considered as an adjunct to basic therapy for COVID-19 disease and its long-term complications. Further studies are planned to determine the clinical value of quercetin supplements in therapy of essential hypertension, rehabilitation of patients after COVID-19, stabilization of dyslipidemia and insulin resistance, as well as dose adjustment and study of possible drug interactions between quercetin and antihypertensive drugs

Keywords: essential hypertension, COVID-19, quercetin, metabolic syndrome

Full text: PDF (Ukr) 282K

  1. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 2017 Jan; 317(2): 165–182. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/28097354.
  2. WHO. Hypertension. Available from:
  3. Gay HC, Rao SG, Vaccarino V, Ali MK. Effects of Different Dietary Interventions on Blood Pressure: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Hypertension. 2016 Apr; 67(4): 733-9. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/26902492.
  4. WHO. Obesity and overweight. Available from:
  5. Zahorodnyi MI, Svintsitskyi IA. Endotelialna dysfunktsiia pry arterialnii hipertenzii: suchasni pohliady na prychyny y mekhanizmy rozvytku, diahnostyku ta korektsiiu [Endothelial dysfunction for arterial hypertension: modern views on the cause and mechanisms of development, diagnosis and correction]. Praktykuiuchyi likar. 2013; (2): 17-27. [Ukrainian]
  6. Musikhina NA, Gapon LI, Petelina TI, Makhneva EA, Emeneva IV. Features of endothelial dysfunction and heart rate variability in arterial hypertension and coronary heart disease. Arterial hypertension. 2016; 22(4): 414-424.
  7. Radenković M, Stojanović M, Potpara T, Prostran M, Therapeutic Approach in the Improvement of Endothelial Dysfunction: The Current State of the Art. BioMed Res Int. 2013; 2013: 252158. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/23509696; HTTPS://WWW.NCBI.NLM.NIH.GOV/PMC/ARTICLES/3581156.
  8. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care. 2009 Nov; 32 Suppl 2(Suppl 2): S314-21. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/19875572; HTTPS://WWW.NCBI.NLM.NIH.GOV/PMC/ARTICLES/2811443.
  9. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005 Apr 21; 352(16): 1685-95. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/15843671.
  10. Crandall JP, Mather K, Rajpathak SN, Goldberg RB, Watson K, Foo S, et al. Statin use and risk of developing diabetes: results from the Diabetes Prevention Program. BMJ Open Diabetes Res Care. 2017; 5(1): e000438. Https://
  11. Ganda OP. Statin-induced diabetes: incidence, mechanisms, and implications. F1000Res. 2016 Jun 24; 5: F1000 Faculty Rev-1499. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/27408693; HTTPS://WWW.NCBI.NLM.NIH.GOV/PMC/ARTICLES/4926726.
  12. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011 Jun 22; 305(24): 2556-64. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/21693744.
  13. Kim J, Lee HS, Lee KY. Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea. Cardiovasc Diabetol. 2018 Dec 5; 17(1): 155. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/30518364. HTTPS://WWW.NCBI.NLM.NIH.GOV/PMC/ARTICLES/6280428.
  14. Sattar NA, Ginsberg H, Ray K, Chapman MJ, Arca M, Averna M, et al. The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. Atheroscler Suppl. 2014 Jun; 15(1): 1-15. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/24840509.
  15. Chekalina NI, Shut`SV, Trybrat TA, Burmak YuH, Petrov YeYe, Manusha TuI, et al. Effect of quercetin on parameters of central hemodynamics and myocardial ischemia in patients with stable coronary heart disease. Wiad Lek. 2017; LXX(4): 707-711.
  16. Andriantsitohaina R, Auger C, Chataigneau T, Étienne-Selloum N, Li H, Martínez MC, et al. Molecular mechanisms of the cardiovascular protective effects of polyphenols. Br J Nutr. 2012 Nov 14; 108(9): 1532-49. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/22935143.
  17. Brüll V, Burak C, Stoffel-Wagner B, Wolffram S, Nickenig G, Müller C, et al. Effects of a quercetin-rich onion skin extract on 24 h ambulatory blood pressure and endothelial function in overweight-to-obese patients with (pre-) hypertension: a randomised double-blinded placebo-controlled cross-over trial. Br J Nutr. 2015 Oct 28; 114(8): 1263-77. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/26328470; HTTPS://WWW.NCBI.NLM.NIH.GOV/PMC/ARTICLES/4594049.
  18. Chekalina N, Burmak Y, Petrov Y, Borisova Z, Manusha Y, Kazakov Y, et al. Quercetin reduces the transcriptional activity of NF-kB in stable coronary artery disease. Indian Heart J. 2018 Sep-Oct; 70(5): 593-597. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/30392493; HTTPS://WWW.NCBI.NLM.NIH.GOV/PMC/ARTICLES/6204471.
  19. Amiot MJ, Riva C, Vinet A. Effects of dietary polyphenols on metabolic syndrome features in humans: a systematic review. Obes Rev. 2016 Jul; 17(7): 573-86. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/27079631.
  20. LaVergne SM, Stromberg S, Baxter BA, Webb TL, Dutt TS, Berry K, et al. A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae. BMC Infect Dis. 2021 Jul 13; 21(1): 677. Https:// doi: 10.1186/s12879-021-06359-2
  21. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021 Apr; 27(4): 601-615. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/33753937.
  22. Shibata S, Arima H, Asayama K, Hoshide S, Ichihara A, Ishimitsu T, et al. Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. Hypertens Res. 2020 Oct; 43(10): 1028-1046. Https://
  23. Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circulation Res. 2020; 126: 1456–74. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/32264791; HTTPS://WWW.NCBI.NLM.NIH.GOV/PMC/ARTICLES/7188049.
  24. Bunyavanich S, Do A, Vicencio A. Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults. JAMA. 2020 Jun 16; 323(23):2427-2429. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/32432657. HTTPS://WWW.NCBI.NLM.NIH.GOV/PMC/ARTICLES/7240631.
  25. Morales DR, Conover MM, You SC, Pratt N, Kostka K, et al. Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis. Lancet Digit Health. Lancet Digit Health. 2021 Feb; 3(2): e98-e114. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/33342753; HTTPS://WWW.NCBI.NLM.NIH.GOV/PMC/ARTICLES/7834915.
  26. Soleimani A, Kazemian S, Karbalai SS, Aminorroaya A, Shajari Z, Hadadi A, et al. Effects of Angiotensin Receptor Blockers (ARBs) on In-Hospital Outcomes of Patients With Hypertension and Confirmed or Clinically Suspected COVID-19. Am J Hypertens. 2020 Dec 31; 33(12): 1102-1111. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/32920644. HTTPS://WWW.NCBI.NLM.NIH.GOV/PMC/ARTICLES/7543264.
  27. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020 Jun 18; 382(25): 2441-2448. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/32356628. HTTPS://WWW.NCBI.NLM.NIH.GOV/PMC/ARTICLES/7206932.
  28. Yanai H. Metabolic Syndrome and COVID-19. Cardiol Res. 2020 Dec; 11(6): 360-365. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/33224380. HTTPS://WWW.NCBI.NLM.NIH.GOV/PMC/ARTICLES/7666594.
  29. Nigro E, Perrotta F, Polito R, D’Agnano V, Scialò F, Bianco A, et al. Metabolic Perturbations and Severe COVID-19 Disease: Implication of Molecular Pathways. Int J Endocrinol. 2020 Nov 28; 2020: 8896536. Https://
  30. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020 Jun; 75(6): 1334-1357. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/32370572.
  31. Shatylo V, Antoniuk-Shcheglova I, Naskalova S, Bondarenko O, Havalko A, Krasnienkov D, et al. Cardio-metabolic benefits of quercetin in elderly patients with metabolic syndrome. Pharma Nutrition. 2021 Mar; 15: 100250.
  32. Tabrizi R, Tamtaji O R, Mirhosseini N, Lankarani KB, Akbari M, Heydari ST, et al. The effects of quercetin supplementation on lipid profiles and inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 2020; 60(11): 1855-1868. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/31017459.
  33. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020 May;109(5):531-538. Https://
  34. Peluso I, Palmery M. Flavonoids at the pharma-nutrition interface: Is a therapeutic index in demand? Biomed Pharmacother. 2015 Apr; 71: 102-7. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/25960223.
  35. Serban MC, Sahebkar A, Zanchetti A, Mikhailidis DP, Howard G, Antal D, et al. Lipid and Blood Pressure Meta‐analysis Collaboration (LBPMC) Group. Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2016 Jul 12; 5(7): e002713. Https://
  36. Colunga Biancatelli RML, Berrill M, Catravas JD, Marik PE. Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19). Front Immunol. 2020 Jun 19; 11: 1451. Https://